Skip to main content
x

Recent articles

Pivotal study designs revealed

Keenly awaited trials of ficerafusp alfa, Trodelvy and divarasib materialise.

Cargo can't replicate firi-cel's academic success

Firce-1 is scrapped after showing dismal response rates and patient deaths.

Zentalis doubles down on Wee1

But the new focus on a predictive biomarker could cut the market in half.

NextCure joins the B7-H4 brigade

Meanwhile, Olema’s KAT6 inhibitor will take on rival projects from Pfizer and Menarini.

A Leap into the subgroups

On a wing and a prayer Leap heads for phase 3.

ASCO-GI – ALX resurrects evorpacept

The company reveals fresh biopsy status as a primary endpoint, and declares Aspen-06 a win.